PERSPECTIVE THERAPEUTICS INC (CATX)

CATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024

CATX stock results show that Perspective Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Continued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation...

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

Insider Bets Paying Off At CATX As New 52-Week High Reached

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering...

Nuclear Medicine Is Big Pharma’s New Target in Cancer Race

As pharma giants spend billions on acquisitions of startups developing new ways to harness radiation in the fight against cancer, the chief executive officer of Perspective Therapeutics Inc. found himself getting top billing at two different industry gatherings this week.

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering...

Perspective Therapeutics Announces $87.4 Million Private Placement

SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate gross proceeds of approximately $87.4 million, before deducting placement agent fees and other offering expenses.

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant...

Insider Bets Paying Off At CATX As New 52-Week High Reached

Monday 1/29 Insider Buying Report: ACET, CATX

Perspective stock gains as B. Riley starts at Buy (NYSE:CATX)

B. Riley launched its coverage of Perspective Therapeutics (CATX) with a Buy rating and a $1.20 per share target citing its radiopharma prospects. Read more here.

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

Perspective Therapeutics announces proposed public offering (NYSE:CATX)

Perspective Therapeutics commences public offering of common stock to certain investors, intending to use proceeds for research, development, and corporate...

Perspective Therapeutics Announces Proposed Public Offering

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for...

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NETLantheus will have the option to co-fund and...

Top Buys by Top Brass: Chief Medical Officer Puhlmann's $188.7K Bet on CATX

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that...

Perspective Therapeutics to divest brachytherapy business (NYSE:CATX)

Perspective Therapeutics sells brachytherapy business to GT Medical, retaining liabilities but gaining equity and royalties on Cesium-131 seed sales.

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NETPreliminary data readout expected in...

Perspective Therapeutics files for $200M mixed shelf (NYSE:CATX)

Perspective Therapeutics (CATX) files mixed shelf offering prospectus for potential $200M raise, non-binding offer to sell securities.